Enhanced Protection of Cyclophosphamide-Treated Mice Against Infection With: Pseudomonas Aeruginosa After Treatment with Z-100. A Polysaccharide-Rich Extract from Mycobacterium Tuberculosis Aoyama B

Abstract

We investigated the effect of Z-100, a polysaccharide-rich extract from Mycobacterium tuberculosis strain Aoyama B, on the protection of immunocompromised mice against infection with Pseudomonas aeruginosa. Mice were given cyclophosphamide and then treated with varying doses of Z-100 for 5 days or left untreated. One day after the completion of the treatment, they were challenged with P. aeruginosa and the mortality was scored. A significantly enhanced protection was observed in the treated group and bacterial number in organs was significantly lower compared with non-treated group. Though the activity of phagocytes did not appear to be activated since there was no difference in chemiluminescence response of peritoneal phagocytes between control and Z-100-treated groups, an enhanced accumulation of phagocytes was observed after bacterial challenge in Z-100-treated group. It was suggested that Z-100 is effective in the restoration of impaired resistance of immuno-compromised mice to bacterial infection possibly through a stimulation of phagocyte accumulation into the site of infection.

Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses

“…1) In previous reports, Z-100 was shown to have various immunopotentiating activities, including enhancement of the granulopoietic activity of the reticuloendothelial system, 2) a protective effect against Pseudomonas aeruginosa infection in immunosuppressed mice, 3) herpes virus infections in thermally injured mice, 4) LP-BM5 murine leukemia virus infection, 5) and induction of cytokines such as IL-1, 6) IL-3, 7) IFN-g 8) and IL-12. 9) In Japan, Z-100 is clinically used in patients with leukopenia caused by radiotherapy.…”

Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages

“…The immunomodulatory activities of Z-100 have been described previously. These include anti-tumour (Sasaki et al, 1993;Suzuki et al, 1986) and anti-metastatic (Emori et al, 1996;Kobayashi et al, 1997) activities against several syngeneic tumours in experimental animals, protective effects against opportunistic infections in immunosuppressed hosts (Kawamura et al, 1990;Sasaki et al, 1997) and cytokine-inducing activities, such as interleukin (IL) 12 (Kobayashi et al, 1995) and interferon (IFN)-c (Hayashi et al, 1981) production in vivo and in vitro. The anti-tumour activities of Z-100 might be due to suppression of tumour-associated Th2-type cytokines, for example IL4 and IL10 (Oka et al, 1999).…”

The effect of combination therapy of radiation and Z-100, an arabinomannan on tumor growth in mice

“…Z-100 has been shown to have various immunopotentiating activities including enhancement of granulopoietic activity of the reticuloendothelial system [2], protective effect against leukopenia induced by X-irradiation [3], protective effect against Pseudornonas aeruginosa infection in immunosuppressed mice [4], and induction of cytokines such as interleukin-I [5], interleukin-3 [6], mitogenic factor [7] and interferon y [8]. Furthermore, Z-100 has been reported to regulate the generation of suppressor cells in tumorbearing hosts [9,10].…”